

December 23, 2025

| | |
|---|---|
| To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA | To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 |
|---|---|

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform that Helix Healthcare B.V., a wholly owned subsidiary of the Company (Helix), has entered into a binding agreement on December 22, 2025 with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China (Shandong Luoxin), the joint venture partner in Luoxin Aurovitas Pharma (Chengdu) Co. Ltd, China (Luoxin Aurovitas), a 30:70 joint venture company between Helix and Shandong Luoxin, to acquire 20% additional ownership in Luoxin Aurovitas.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as '**Annexure A**'.

This is for your information and records.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: Annexure A

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure -A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

| | |
|---|---|
| a) Name of the target entity, details in brief such as size, turnover etc.; | Luoxin Aurovitas Pharma (Chengdu) Co. Ltd, China ("Luoxin Aurovitas") is a 30:70 joint venture company between Helix Healthcare B.V., The Netherlands ("Helix"), a wholly owned subsidiary of the Company and Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China ("Shandong Luoxin"). It has registered a turnover of USD 2.34 mn during FY 2024-25 and has a net worth of USD 15.29 mn as on September 30, 2025. |
| b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length"; | <p>The proposed acquisition of 20% additional ownership in Luoxin Aurovitas would fall within the related party transaction since Luoxin Aurovitas is a joint venture company.</p> <p>Promoter / promoter group / group companies have no interest in Luoxin Aurovitas, the entity in which additional 20% is proposed to be acquired by Helix and also in Shandong Luoxin, the other joint venture partner.</p> <p>The transaction is at arms-length price based on third party valuation.</p> |
| c) Industry to which the business of the target entity being acquired belongs; | Pharmaceutical industry |
| d) Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); | Object of acquisition is to expand the manufacturing to economies of scale by adding 2 high Speed Lines and cater market demand. |
| e) Brief details of any governmental or regulatory approvals required for the | No governmental or regulatory approvals are required for the proposed acquisition. |
| f) Indicative time period for completion of the acquisition. | The initial acquisition of 20% stake would be acquired within next three months with the right to acquire balance 50% stake by December 2029 at an agreed price of USD 18.86 mn subject to certain terms and conditions. |
| g) Nature of consideration - whether cash consideration or share swap or any other form and details of the same; | Cash consideration. |
| h) Cost of acquisition and / or the price at which the shares are acquired; | USD 5.125 mn for acquisition of 20% share in Luoxin Aurovitas. |
| i) Percentage of shareholding / control acquired and or number of shares acquired; | 20% shares |

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);

Luoxin Aurovitas was set up as a joint venture company for manufacturing Inhalation products in China on March 25, 2019. Last three years turnover details are provided below:

| Year | Turnover in USD mn |
|---------|--------------------|
| 2024-25 | 2.34 |
| 2023-24 | 0.48 |
| 2022-23 | 0.16 |

The current net worth of Luoxin Aurovitas is USD 15.29 mn.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com